 Connection
Ana Gleisner to Tumor Burden
This is a "connection" page, showing publications Ana Gleisner has written about Tumor Burden.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.734 |
|
|
|
-
Akabane M, Baldo A, Kawashima J, Woldesenbet S, Lesurty M, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. Beyond the composite: Differential impact of albumin and bilirubin relative to tumor burden in HCC. Eur J Surg Oncol. 2026 Feb; 52(2):111309.
Score: 0.211
-
Kawashima J, Akabane M, Khalil M, Woldesenbet S, Endo Y, Sahara K, Cauchy F, Aucejo F, Marques HP, Lopes R, Rodriguea A, Hugh T, Shen F, Maithel SK, Groot Koerkamp B, Popescu I, Kitago M, Weiss MJ, Martel G, Pulitano C, Aldrighetti L, Poultsides G, Ruzzenente A, Bauer TW, Gleisner A, Endo I, Pawlik TM. Tumour burden predicts outcomes after curative resection of multifocal intrahepatic cholangiocarcinoma. Br J Surg. 2025 03 28; 112(4).
Score: 0.202
-
Kawashima J, Endo Y, Woldesenbet S, Khalil M, Akabane M, Cauchy F, Shen F, Maithel S, Popescu I, Kitago M, Weiss MJ, Martel G, Pulitano C, Aldrighetti L, Poultsides G, Ruzzente A, Bauer TW, Gleisner A, Marques H, Groot Koerkamp B, Endo I, Pawlik TM. The Influence of Tumor Burden Score and Lymph Node Metastasis on the Survival Benefit of Adjuvant Chemotherapy in Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2025 Jun; 32(6):4341-4351.
Score: 0.200
-
Akabane M, Kawashima J, Woldesenbet S, Altaf A, Cauchy F, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. Analyzing the interaction between time to surgery and tumor burden score in hepatocellular carcinoma. J Gastrointest Surg. 2025 02; 29(2):101903.
Score: 0.197
-
Akabane M, Kawashima J, Woldesenbet S, Macedo AB, Cauchy F, Shen F, Maithel SK, Groot Koerkamp B, Alexandrescu S, Kitago M, Weiss M, Martel G, Pulitano C, Aldrighetti L, Poultsides GA, Imaoka Y, Guglielmi A, Bauer TW, Endo I, Gleisner A, Marques HP, Pawlik TM. Improving Recurrence Prediction in Intrahepatic Cholangiocarcinoma: The Synergistic Impact of the FIB-4 Index and Tumor Burden Score on Post-hepatectomy Outcomes. Ann Surg Oncol. 2025 Feb; 32(2):1011-1020.
Score: 0.197
-
Endo Y, Tsilimigras DI, Munir MM, Woldesenbet S, Yang J, Guglielmi A, Ratti F, Marques HP, Cauchy F, Lam V, Poultsides GA, Kitago M, Popescu I, Alexandrescu S, Martel G, Gleisner A, Hugh T, Aldrighetti L, Shen F, Endo I, Pawlik TM. Prognostic significance of postoperative complications for patients with hepatocellular carcinoma relative to alpha-feto protein and tumor burden score. HPB (Oxford). 2024 08; 26(8):998-1006.
Score: 0.189
-
Yuza K, Kawashima J, Chatzipanagiotou OP, Hobeika C, Aucejo F, Marques HP, Hugh T, Shen F, Maithel SK, Koerkamp BG, Popescu I, Kitago M, Weiss MJ, Martel G, Pulitano C, Poultsides G, Ruzzenente A, Bauer TW, Gleisner A, Endo I, Pawlik TM. Biologic stratification with tumor burden score and CA19-9 to inform vascular resection in intrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2026 May; 52(5):111750.
Score: 0.054
-
Akabane M, Kawashima J, Woldesenbet S, Cauchy F, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. International validation of a natural-killer-cell-based model to predict recurrence-free survival in hepatocellular carcinoma. HPB (Oxford). 2025 Oct; 27(10):1259-1269.
Score: 0.051
-
Kawashima J, Akabane M, Khalil M, Woldesenbet S, Endo Y, Sahara K, Ruzzenente A, Ratti F, Marques HP, Oliveira S, Balaia J, Cauchy F, Lam V, Poultsides GA, Kitago M, Popescu I, Martel G, Gleisner A, Hugh T, Weiss M, Aucejo F, Aldrighetti L, Endo I, Pawlik TM. Model of End-Stage Liver Disease-alpha-fetoprotein-tumor burden (MELD-AFP-TBS) score to stratify prognosis after liver resection for hepatocellular carcinoma. Surgery. 2025 Jul; 183:109388.
Score: 0.051
-
Akabane M, Kawashima J, Altaf A, Woldesenbet S, Cauchy F, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Oliveira S, Balaia J, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. Enhancing Recurrence-Free Survival Prediction in Hepatocellular Carcinoma: A Time-Updated Model Incorporating Tumor Burden and AFP Dynamics. Ann Surg Oncol. 2025 Aug; 32(8):5648-5656.
Score: 0.051
-
Kawashima J, Akabane M, Khalil M, Woldesenbet S, Endo Y, Sahara K, Cauchy F, Aucejo F, Marques HP, Lopes R, Rodriguea A, Hugh T, Shen F, Maithel SK, Groot Koerkamp B, Popescu I, Kitago M, Weiss MJ, Martel G, Pulitano C, Aldrighetti L, Poultsides G, Ruzzente A, Bauer TW, Gleisner A, Endo I, Troisi RI, Pawlik TM. Impact of Tumor Size on the Survival Benefit of Anatomic Versus Non-Anatomic Resection for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2025 Aug; 32(8):5637-5647.
Score: 0.051
-
Catalano G, Alaimo L, Chatzipanagiotou OP, Ruzzenente A, Ratti F, Aldrighetti L, Marques HP, Cauchy F, Lam V, Poultsides GA, Hugh T, Popescu I, Alexandrescu S, Martel G, Kitago M, Endo I, Gleisner A, Shen F, Pawlik TM. Predicting the complexity of minimally invasive liver resection for hepatocellular carcinoma using machine learning. HPB (Oxford). 2025 Jun; 27(6):807-815.
Score: 0.050
-
Akabane M, Kawashima J, Altaf A, Woldesenbet S, Cauchy F, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. Impact of disparity between imaging and pathological tumor size on cancer-specific prognosis among patients with hepatocellular carcinoma. Eur J Surg Oncol. 2025 06; 51(6):109683.
Score: 0.050
-
Altaf A, Khalil M, Akabane M, Rashid Z, Kawashima J, Zindani S, Ruzzenente A, Ratti F, Marques H, Cauchy F, Lam V, Poultsides G, Aucejo F, Kitago M, Popescu I, Martel G, Gleisner A, Bauer TW, Hugh T, Bhimani N, Shen F, Endo I, Pawlik TM. Up-front resection for hepatocellular carcinoma: Assessing futility in the preoperative setting. Eur J Surg Oncol. 2025 05; 51(5):109594.
Score: 0.050
-
Endo Y, Moazzam Z, Alaimo L, Woldesenbet S, Lima HA, Munir MM, Katayama E, Yang J, Azap L, Shaikh CF, Ratti F, Marques HP, Cauchy F, Lam V, Poultsides GA, Kitago M, Popescu I, Alexandrescu S, Martel G, Guglielmi A, Gleisner A, Hugh T, Aldrighetti L, Shen F, Endo I, Pawlik TM. Modified integrated tumor burden, liver function, systemic inflammation, and tumor biology score to predict long-term outcomes after resection for hepatocellular carcinoma. HPB (Oxford). 2023 12; 25(12):1484-1493.
Score: 0.045
-
Endo Y, Munir MM, Woldesenbet S, Katayama E, Ratti F, Marques HP, Cauchy F, Lam V, Poultsides GA, Kitago M, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Gleisner A, Hugh T, Aldrighetti L, Shen F, Endo I, Pawlik TM. Impact of Surgical Margin Width on Prognosis Following Resection of Hepatocellular Carcinoma Varies on the Basis of Preoperative Alpha-Feto Protein and Tumor Burden Score. Ann Surg Oncol. 2023 Oct; 30(11):6581-6589.
Score: 0.045
-
Oba A, Croce C, Hosokawa P, Meguid C, Torphy RJ, Al-Musawi MH, Ahrendt S, Gleisner A, Schulick RD, Del Chiaro M. Prognosis Based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines. Ann Surg. 2022 01 01; 275(1):175-181.
Score: 0.040
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|